Q1 25 EPS
$-1.36
BEAT +0.23%
Est. $-1.36
Q1 25 Revenue
$1.6M
MISS 39.51%
Est. $2.6M
vs S&P Since Q1 25
+115.0%
BEATING MARKET
CYTK +147.8% vs S&P +32.9%
Market Reaction
Did CYTK Beat Earnings? Q1 2025 Results
Cytokinetics posted a narrow earnings beat in Q1 2025 but fell well short on revenue, as the pre-commercial biopharma company continues to absorb heavy spending ahead of a potential aficamten launch. The loss per share of $1.36 edged past the consens… Read more Cytokinetics posted a narrow earnings beat in Q1 2025 but fell well short on revenue, as the pre-commercial biopharma company continues to absorb heavy spending ahead of a potential aficamten launch. The loss per share of $1.36 edged past the consensus estimate of $1.36 by 0.23%, while collaboration revenue of $1.58 million, up 89.1% year over year, missed the $2.61 million consensus by 39.51%, reflecting the company's still-modest partnership income base. The deeper story is one of deliberate investment: R&D expenses climbed to $99.84 million from $81.57 million a year ago, and G&A costs rose to $57.37 million from $45.50 million, as Cytokinetics builds out its commercial infrastructure for aficamten in obstructive hypertrophic cardiomyopathy. A recently announced Phase 3 MAPLE-HCM trial showed aficamten superior to metoprolol in improving peak oxygen uptake, adding clinical momentum ahead of aficamten's December 26, 2025 PDUFA date. Full-year operating expense guidance remains $670 million to $710 million, reflecting continued commercial readiness investments through the anticipated launch window.
Key Takeaways
- • Higher R&D expenses driven by advancing clinical trials and higher personnel-related costs
- • Higher G&A expenses driven by investments in commercial readiness and higher personnel-related costs
- • Collaboration revenues increased to $1.6 million from $0.8 million year-over-year
CYTK YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
CYTK Revenue by Segment
With YoY comparisons, source: SEC Filings
“In the first quarter, we made progress towards commercial readiness and advanced our specialty cardiology pipeline. Recently, our PDUFA date for aficamten in obstructive HCM was extended by FDA to provide time to review a REMS submission made at the Agency's request subsequent to the initial NDA filing acceptance. We remain confident in the distinct benefit-risk and pharmaceutic profile of aficamten, and our top priority is bringing this potential therapy to patients. This month, we also expect to report topline results from MAPLE-HCM, and we continue conduct of ACACIA-HCM, for which we have now completed enrollment of patients. With a strong balance sheet and prudent attention to capital deployment, we are well positioned to deliver across regulatory, clinical and commercial milestones.”
— Robert I. Blum, Q1 2025 Earnings Press Release
CYTK Earnings Trends
CYTK vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CYTK EPS Trend
Earnings per share: estimate vs actual
CYTK Revenue Trend
Quarterly revenue: estimate vs actual
CYTK Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-1.63 | $-1.67 | -2.31% | $19.4M | +113.25% |
| Q4 25 MISS FY | $-1.37 | $-1.50 | -9.67% | $17.8M | +121.30% |
| FY Full Year | — | $-6.54 | — | $88.0M | — |
| Q3 25 MISS | $-1.63 | $-2.55 | -56.33% | $1.9M | -69.88% |
| Q2 25 BEAT | $-1.34 | $-1.12 | +16.12% | $66.8M | +3,131.07% |
| Q1 25 BEAT | $-1.36 | $-1.36 | +0.23% | $1.6M | -39.51% |